$ICUI
ICU Medical Inc

2015 Q1 Form 10-Q Financial Statement

#000088398415000019 Filed on May 06, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q1
Revenue $81.48M $79.90M $73.23M
YoY Change 11.27% 2.51% -1.44%
Cost Of Revenue $38.97M $40.20M $37.20M
YoY Change 4.75% 3.08% -0.81%
Gross Profit $42.51M $39.69M $36.03M
YoY Change 18.01% 1.9% -2.08%
Gross Profit Margin 52.17% 49.67% 49.2%
Selling, General & Admin $20.17M $20.30M $22.52M
YoY Change -10.41% -1.46% -1.52%
% of Gross Profit 47.45% 51.15% 62.51%
Research & Development $4.308M $5.100M $3.631M
YoY Change 18.65% 45.71% 90.8%
% of Gross Profit 10.13% 12.85% 10.08%
Depreciation & Amortization $4.629M $4.800M $4.765M
YoY Change -2.85% -4.0% 1.12%
% of Gross Profit 10.89% 12.1% 13.23%
Operating Expenses $31.54M $25.30M $26.15M
YoY Change 20.62% 5.42% 5.58%
Operating Profit $10.97M $14.39M $9.877M
YoY Change 11.1% -3.75% -17.86%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $526.0K $200.0K $210.0K
YoY Change 150.48% 0.0% 25.0%
Pretax Income $11.50M $12.20M $10.09M
YoY Change 14.0% -11.59% -17.27%
Income Tax $1.813M $4.900M $3.430M
% Of Pretax Income 15.77% 40.16% 34.0%
Net Earnings $9.686M $7.372M $6.657M
YoY Change 45.5% -44.7% -23.35%
Net Earnings / Revenue 11.89% 9.23% 9.09%
Basic Earnings Per Share $0.62 $0.48 $0.44
Diluted Earnings Per Share $0.60 $0.46 $0.43
COMMON SHARES
Basic Shares Outstanding 15.69M shares 15.37M shares 15.10M shares
Diluted Shares Outstanding 16.23M shares 15.40M shares

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $354.8M $346.8M $303.8M
YoY Change 16.79% 16.81% 30.05%
Cash & Equivalents $308.5M $275.8M $227.6M
Short-Term Investments $46.30M $71.00M $76.20M
Other Short-Term Assets $14.00M $10.50M $12.50M
YoY Change 12.0% -10.26% 15.74%
Inventory $37.66M $36.93M $36.69M
Prepaid Expenses
Receivables $42.60M $39.05M $43.32M
Other Receivables $4.900M $3.900M $4.500M
Total Short-Term Assets $454.0M $432.5M $400.7M
YoY Change 13.29% 9.7% 19.93%
LONG-TERM ASSETS
Property, Plant & Equipment $82.29M $86.09M $90.38M
YoY Change -8.95% -2.01% 3.89%
Goodwill $1.478M $1.478M $1.478M
YoY Change 0.0% 0.0% 0.0%
Intangibles $6.657M $7.063M $8.013M
YoY Change -16.92% -16.81% -16.94%
Long-Term Investments
YoY Change
Other Assets $9.900M $9.300M $5.800M
YoY Change 70.69% 24.0% 3.57%
Total Long-Term Assets $100.3M $108.6M $105.7M
YoY Change -5.08% 3.06% 1.87%
TOTAL ASSETS
Total Short-Term Assets $454.0M $432.5M $400.7M
Total Long-Term Assets $100.3M $108.6M $105.7M
Total Assets $554.3M $541.1M $506.4M
YoY Change 9.46% 8.3% 15.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.55M $11.38M $11.71M
YoY Change 7.12% 0.38% 6.11%
Accrued Expenses $20.35M $17.35M $13.79M
YoY Change 47.6% 11.57% -5.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.90M $28.73M $25.50M
YoY Change 29.0% 6.85% -0.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.200M $2.700M $2.700M
YoY Change -55.56% -38.64% -18.18%
Total Long-Term Liabilities $1.200M $2.700M $2.700M
YoY Change -55.56% -38.64% -18.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.90M $28.73M $25.50M
Total Long-Term Liabilities $1.200M $2.700M $2.700M
Total Liabilities $36.20M $32.90M $32.20M
YoY Change 12.42% -5.73% -6.4%
SHAREHOLDERS EQUITY
Retained Earnings $418.6M $408.9M $389.2M
YoY Change 7.54% 6.88% 10.94%
Common Stock $119.9M $108.9M $84.56M
YoY Change 41.84% 36.11% 25.8%
Preferred Stock
YoY Change
Treasury Stock (at cost) $795.0K $0.00 $1.706M
YoY Change -53.4% -100.0% -84.17%
Treasury Stock Shares 9.000K shares 0.000 shares 27.00K shares
Shareholders Equity $518.1M $508.3M $474.2M
YoY Change
Total Liabilities & Shareholders Equity $554.3M $541.1M $506.4M
YoY Change 9.46% 8.3% 15.65%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q1
OPERATING ACTIVITIES
Net Income $9.686M $7.372M $6.657M
YoY Change 45.5% -44.7% -23.35%
Depreciation, Depletion And Amortization $4.629M $4.800M $4.765M
YoY Change -2.85% -4.0% 1.12%
Cash From Operating Activities $13.25M $12.30M $12.71M
YoY Change 4.22% -47.66% 18.12%
INVESTING ACTIVITIES
Capital Expenditures $2.357M -$2.000M $5.908M
YoY Change -60.1% -41.18% 1.32%
Acquisitions
YoY Change
Other Investing Activities $22.60M $5.300M -$6.000M
YoY Change -476.67% 231.25% 650.0%
Cash From Investing Activities $20.02M $3.400M -$12.00M
YoY Change -266.86% -288.89% 71.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.435M $5.835M
YoY Change -75.41%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $7.442M 10.80M $929.0K
YoY Change 701.08% -29.87% -82.15%
NET CHANGE
Cash From Operating Activities $13.25M 12.30M $12.71M
Cash From Investing Activities $20.02M 3.400M -$12.00M
Cash From Financing Activities $7.442M 10.80M $929.0K
Net Change In Cash $40.71M 26.50M $1.648M
YoY Change 2370.15% -28.57% -81.63%
FREE CASH FLOW
Cash From Operating Activities $13.25M $12.30M $12.71M
Capital Expenditures $2.357M -$2.000M $5.908M
Free Cash Flow $10.89M $14.30M $6.806M
YoY Change 60.06% -46.84% 37.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000883984
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15777942 shares
CY2015Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
ICU MEDICAL INC/DE
CY2015Q1 icui Debt Securities Maturity Date Range High
DebtSecuritiesMaturityDateRangeHigh
2045
CY2015Q1 icui Debt Securities Maturity Date Range Low
DebtSecuritiesMaturityDateRangeLow
2015
CY2014Q1 icui Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
1956000 USD
CY2015Q1 icui Increase Decreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
IncreaseDecreaseinincometaxesincludingexcesstaxbenefitsanddeferredincometaxes
-2392000 USD
CY2015Q1 icui Legal Settlement Charge For Legal Fees
LegalSettlementChargeForLegalFees
600000 USD
CY2015Q1 icui Legalsettlementaccrual
Legalsettlementaccrual
7100000 USD
CY2015Q1 icui Legalsettlementcharge
Legalsettlementcharge
6500000 USD
CY2014Q1 icui Provision For Warranty And Returns
ProvisionForWarrantyAndReturns
-410000 USD
CY2015Q1 icui Provision For Warranty And Returns
ProvisionForWarrantyAndReturns
31000 USD
CY2015Q1 icui Treasury Stock Purchase Plan
TreasuryStockPurchasePlan
40000000 USD
CY2015Q1 icui Treasury Stock Purchase Plan Remaining Available
TreasuryStockPurchasePlanRemainingAvailable
22500000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11378000 USD
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
12548000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39051000 USD
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42595000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17350000 USD
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20349000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
138623000 USD
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
141738000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9554000 USD
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19645000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
107336000 USD
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
118367000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1127000 USD
CY2015Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1046000 USD
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
237000 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
76000 shares
CY2014Q4 us-gaap Assets
Assets
541102000 USD
CY2015Q1 us-gaap Assets
Assets
554344000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
437212000 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
454010000 USD
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
70952000 USD
CY2015Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
46254000 USD
CY2014Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1008000 USD
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
144000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226022000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
227623000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275812000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
308533000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1601000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
32721000 USD
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
346764000 USD
CY2015Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
354787000 USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15595000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15778000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15595000 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15769000 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1559000 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
1578000 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6581000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-405000 USD
CY2014Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0 USD
CY2015Q1 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0 USD
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
37203000 USD
CY2015Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
38970000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
4683000 USD
CY2015Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
7393000 USD
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9258000 USD
CY2015Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9911000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1376000 USD
CY2015Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2123000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4765000 USD
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4629000 USD
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.60
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-47000 USD
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-7987000 USD
CY2014Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.34
CY2015Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.16
CY2014Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1178000 USD
CY2015Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
3059000 USD
CY2014Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5000 USD
CY2015Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000 USD
CY2014Q4 us-gaap Goodwill
Goodwill
1478000 USD
CY2015Q1 us-gaap Goodwill
Goodwill
1478000 USD
CY2014Q1 us-gaap Gross Profit
GrossProfit
36027000 USD
CY2015Q1 us-gaap Gross Profit
GrossProfit
42514000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
10087000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
11499000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3430000 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1813000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
382000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1951000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2416000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4947000 USD
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2557000 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3300000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2267000 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1785000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
800000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
980000 USD
CY2014Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
298000 shares
CY2015Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
541000 shares
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7063000 USD
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6657000 USD
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10381000 USD
CY2015Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11622000 USD
CY2014Q4 us-gaap Inventory Net
InventoryNet
36933000 USD
CY2015Q1 us-gaap Inventory Net
InventoryNet
37660000 USD
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
23006000 USD
CY2015Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
20912000 USD
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3546000 USD
CY2015Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
5126000 USD
CY2014Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
601000 USD
CY2015Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
943000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
541102000 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
554344000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
28728000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
32897000 USD
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
2746000 USD
CY2015Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1222000 USD
CY2014Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
CY2015Q1 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
7059000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
929000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7442000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11995000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20015000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12714000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13251000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
210000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
526000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
26150000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
31541000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
9877000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
10973000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-76000 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-10091000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-21000 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-2720000 USD
CY2014Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
117000 USD
CY2015Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
161000 USD
CY2015Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1400000 USD
CY2014Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
120000 USD
CY2015Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
208000 USD
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
36908000 USD
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
9205000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5908000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2357000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5818000 USD
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6634000 USD
CY2014Q4 us-gaap Prepaid Taxes
PrepaidTaxes
3963000 USD
CY2015Q1 us-gaap Prepaid Taxes
PrepaidTaxes
4941000 USD
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30936000 USD
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31785000 USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000 USD
CY2015Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4202000 USD
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4777000 USD
CY2014Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1384000 USD
CY2015Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1041000 USD
CY2014Q1 us-gaap Profit Loss
ProfitLoss
6657000 USD
CY2015Q1 us-gaap Profit Loss
ProfitLoss
9686000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
224714000 USD
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
224026000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86091000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
82288000 USD
CY2014Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3000 USD
CY2015Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3631000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4308000 USD
CY2015Q1 us-gaap Restructuring Reserve
RestructuringReserve
600000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
408911000 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
418597000 USD
CY2014Q1 us-gaap Revenues
Revenues
73230000 USD
CY2015Q1 us-gaap Revenues
Revenues
81484000 USD
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
73113000 USD
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
81323000 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22519000 USD
CY2015Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20174000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1973000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2813000 USD
CY2015Q1 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
16401 shares
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
508252000 USD
CY2015Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
518102000 USD
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
CY2015Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
9000 shares
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2015Q1 us-gaap Treasury Stock Value
TreasuryStockValue
795000 USD
CY2014Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-5835000 USD
CY2015Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-1435000 USD
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15395000 shares
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16234000 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15097000 shares
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15693000 shares
CY2015Q1 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&#160; If these proposed changes are finalized, this standard would require public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption would be permitted as of the original effective date in ASU 2014-09. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the FASB issued ASU No. 2014-12, Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. The amendments in ASU 2014-12 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in ASU 2014-12 either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. This guidance will become effective for us at the beginning of the first quarter of 2016. We do not anticipate a material impact on our consolidated financial statements from adoption of this ASU.</font></div></div>

Files In Submission

Name View Source Status
0000883984-15-000019-index-headers.html Edgar Link pending
0000883984-15-000019-index.html Edgar Link pending
0000883984-15-000019.txt Edgar Link pending
0000883984-15-000019-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
icui-20150331.xml Edgar Link completed
icui-20150331.xsd Edgar Link pending
icui-20150331_cal.xml Edgar Link unprocessable
icui-20150331_def.xml Edgar Link unprocessable
icui-20150331_lab.xml Edgar Link unprocessable
icui-20150331_pre.xml Edgar Link unprocessable
icui-ex311_20150331x10q.htm Edgar Link pending
icui-ex312_x20150331x10q.htm Edgar Link pending
icui-ex321_x20150331x10q.htm Edgar Link pending
icui0331201510-q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending